FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1906580765> ?p ?o ?g. }

• W1906580765 endingPage "172" @default.
• W1906580765 startingPage "163" @default.
• W1906580765 abstract "Background and purpose The EORTC trial No. 22972 investigated the role of an additional fractionated stereotactic boost (fSRT) to conventional radiotherapy for patients with high grade gliomas. A quality-assurance (QA) programme was run in conjunction with the study and was the first within the EORTC addressing the quality of a supposedly highly accurate treatment technique such as stereotactic radiotherapy. A second aim was to investigate a possible relation between the clinical results of the stereotactic boost arm and the results of the QA. Materials and methods The trial was closed in 2001 due to low accrual. In total, 25 patients were randomized: 14 into the experimental arm and 11 into the control arm. Six centres randomized patients, 8 centres had completed the dummy run (DR) for the stereotactic boost part. All participating centres (9) were asked to complete a quality-assurance questionnaire. The DR consisted of treatment planning according to the guidelines of the protocol on 3 different tumour volumes drawn on CT images of a humanized phantom. The SRT technique to be used was evaluated by the questionnaire. Clinical data from patients recruited to the boost arm from 6 participating centres were analysed. Results There was a full compliance to the protocol requirements for 5 centres. Major and minor deviations in conformality were observed for 2 and 3 centres, respectively. Of the 8 centres which completed the DR, one centre did not comply with the requirements of stereotactic radiotherapy concerning accuracy, dosimetry and planning. Median follow-up and median overall survival were 39.2 and 21.4 months, respectively. Acute and late toxicities of the stereotactic boost were low. One radiation necrosis was seen for a patient who has not received the SRT boost. Three reported serious adverse events were all seizures and probably therapy-related. Conclusions Overall compliance was good but not ideal from the point of view of this highly precise radiation technique. Survival in the subgroup of patients with small volume disease was encouraging, but the study does not provide sufficient information about the potential value of fSRT boost in patients with malignant glioma.Toxicity due to an additional stereotactic boost of 20 Gy in 4 fractions was low and may be considered as a safe treatment option for patients with small tumours." @default.
• W1906580765 created "2016-06-24" @default.
• W1906580765 creator A5047879448 @default.
• W1906580765 creator A5065243074 @default.
• W1906580765 creator A5069088545 @default.
• W1906580765 creator A5070849285 @default.
• W1906580765 creator A5077700875 @default.
• W1906580765 creator A5079004439 @default.
• W1906580765 creator A5082944210 @default.
• W1906580765 date "2008-08-01" @default.
• W1906580765 modified "2023-09-23" @default.
• W1906580765 title "EORTC 22972–26991/MRC BR10 trial: Fractionated stereotactic boost following conventional radiotherapy of high grade gliomas" @default.
• W1906580765 cites W1442922305 @default.
• W1906580765 cites W1564726563 @default.
• W1906580765 cites W1568283073 @default.
• W1906580765 cites W1871251518 @default.
• W1906580765 cites W1967032465 @default.
• W1906580765 cites W1973108844 @default.
• W1906580765 cites W1983790970 @default.
• W1906580765 cites W2001660159 @default.
• W1906580765 cites W2003914605 @default.
• W1906580765 cites W2009596977 @default.
• W1906580765 cites W2012466686 @default.
• W1906580765 cites W2013575448 @default.
• W1906580765 cites W2014323633 @default.
• W1906580765 cites W2017344875 @default.
• W1906580765 cites W2024992561 @default.
• W1906580765 cites W2031625260 @default.
• W1906580765 cites W2041508331 @default.
• W1906580765 cites W2048925744 @default.
• W1906580765 cites W2050009940 @default.
• W1906580765 cites W2050817216 @default.
• W1906580765 cites W2057531351 @default.
• W1906580765 cites W2066086357 @default.
• W1906580765 cites W2079877074 @default.
• W1906580765 cites W2084859122 @default.
• W1906580765 cites W2084948367 @default.
• W1906580765 cites W2085962524 @default.
• W1906580765 cites W2089885248 @default.
• W1906580765 cites W2125367414 @default.
• W1906580765 cites W2149690332 @default.
• W1906580765 cites W2285627949 @default.
• W1906580765 cites W2397212311 @default.
• W1906580765 cites W2398091317 @default.
• W1906580765 cites W2009287899 @default.
• W1906580765 doi "https://doi.org/10.1016/j.radonc.2008.03.025" @default.
• W1906580765 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18455252" @default.
• W1906580765 hasPublicationYear "2008" @default.
• W1906580765 type Work @default.
• W1906580765 sameAs 1906580765 @default.
• W1906580765 citedByCount "17" @default.
• W1906580765 countsByYear W19065807652012 @default.
• W1906580765 countsByYear W19065807652013 @default.
• W1906580765 countsByYear W19065807652014 @default.
• W1906580765 countsByYear W19065807652015 @default.
• W1906580765 countsByYear W19065807652016 @default.
• W1906580765 countsByYear W19065807652018 @default.
• W1906580765 countsByYear W19065807652022 @default.
• W1906580765 crossrefType "journal-article" @default.
• W1906580765 hasAuthorship W1906580765A5047879448 @default.
• W1906580765 hasAuthorship W1906580765A5065243074 @default.
• W1906580765 hasAuthorship W1906580765A5069088545 @default.
• W1906580765 hasAuthorship W1906580765A5070849285 @default.
• W1906580765 hasAuthorship W1906580765A5077700875 @default.
• W1906580765 hasAuthorship W1906580765A5079004439 @default.
• W1906580765 hasAuthorship W1906580765A5082944210 @default.
• W1906580765 hasConcept C106436119 @default.
• W1906580765 hasConcept C126322002 @default.
• W1906580765 hasConcept C126838900 @default.
• W1906580765 hasConcept C141071460 @default.
• W1906580765 hasConcept C142724271 @default.
• W1906580765 hasConcept C168563851 @default.
• W1906580765 hasConcept C19527891 @default.
• W1906580765 hasConcept C204787440 @default.
• W1906580765 hasConcept C2778618615 @default.
• W1906580765 hasConcept C2780385302 @default.
• W1906580765 hasConcept C2780387249 @default.
• W1906580765 hasConcept C2989005 @default.
• W1906580765 hasConcept C2992393070 @default.
• W1906580765 hasConcept C509974204 @default.
• W1906580765 hasConcept C535046627 @default.
• W1906580765 hasConcept C71924100 @default.
• W1906580765 hasConceptScore W1906580765C106436119 @default.
• W1906580765 hasConceptScore W1906580765C126322002 @default.
• W1906580765 hasConceptScore W1906580765C126838900 @default.
• W1906580765 hasConceptScore W1906580765C141071460 @default.
• W1906580765 hasConceptScore W1906580765C142724271 @default.
• W1906580765 hasConceptScore W1906580765C168563851 @default.
• W1906580765 hasConceptScore W1906580765C19527891 @default.
• W1906580765 hasConceptScore W1906580765C204787440 @default.
• W1906580765 hasConceptScore W1906580765C2778618615 @default.
• W1906580765 hasConceptScore W1906580765C2780385302 @default.
• W1906580765 hasConceptScore W1906580765C2780387249 @default.
• W1906580765 hasConceptScore W1906580765C2989005 @default.
• W1906580765 hasConceptScore W1906580765C2992393070 @default.
• W1906580765 hasConceptScore W1906580765C509974204 @default.
• W1906580765 hasConceptScore W1906580765C535046627 @default.
• W1906580765 hasConceptScore W1906580765C71924100 @default.

• next